Schema



Total 360 for Step 1

1. Tumor tissue must be submitted at preregistration for central review to determine patient eligibility. See Section 10 for collection and submission instructions. 720 patients will be screened in step 0.
2. EGCG: (-)-epigallocatechin-3-gallate. Each 300mg capsule of Sunphenon® 90D/Placebo contains 135mg EGCG/capsule.
3. After 6 months on treatment, there is a mandatory end-of-study (EOS) biopsy.

3. Selection of Patients

Each of the criteria in the checklist that follows must be met in order for a patient to be considered eligible for this study. Use the checklist to confirm a patient's eligibility. For each patient, this checklist must be photocopied, completed and maintained in the patient's chart.

In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday four weeks later would be considered Day 28.

ECOG-ACRIN Patient No. _____

Patient's Initials (L, F, M) _

Physician Signature and Date _____

NOTE: CTEP Policy does not allow for the issuance of waivers to any protocol specified criteria (http://ctep.cancer.gov/protocolDevelopment/policies_deviations.htm). Therefore, all eligibility criteria listed in Section 3 must be met, without exception. The registration of individuals who do not meet all criteria listed in Section 3 can result in the participant being censored from the analysis of the study, and the citation of a major protocol violation during an audit. All questions regarding clarification of eligibility criteria must be directed to the Group's Executive Officer (EA.ExecOfficer@jimmy.harvard.edu) or the Group's Regulatory Officer (EA.RegOfficer@jimmy.harvard.edu).

NOTE: Institutions may use the eligibility checklist as source documentation if it has been reviewed, signed, and dated prior to registration/randomization by the treating physician.

NOTE: This study involves a Step 0 preregistration (screening) and a Step 1 randomization. Tumor tissue specimen must be submitted anytime during screening for Gleason score and % Ki-67 Expression confirmation for eligibility and stratification prior to Step 1 randomization. Patients will not be randomized without Gleason Score and % Ki-67 results.

3.1 Eligibility Criteria for Preregistration (Step 0: Screening):

_____3.1.1 Patient must be ≥ 21 years of age.

_____3.1.2 Patient must speak English or Spanish.

_____3.1.3 Patient must have biopsy-proven (consisting of ≥ 12 tissue cores) adenocarcinoma of the prostate with cancer present in at least one biopsy core in the most recent biopsy using initial TRUS biopsy or TRUS biopsy followed by multiparametric Magnetic Resonance Imaging (mpMRI) of the prostate and a confirmatory targeted biopsy.

Rev Add 1 _____ 3.1.4 Patient must be on active surveillance [local – Gleason 3+3 or Gleason 3+4) very low, low and favorable intermediate risk as defined by the National Comprehensive Cancer Network (NCCN)].

_____3.1.5 Patient's baseline biopsy must have occurred at least 6 months but not more than 18 months prior to preregistration to Step 0.

NOTE: Patient is to be scheduled for a follow-up prostate biopsy 6 months after the initiation of treatment on this study.

_____3.1.6 Patient must have a serum PSA < 10 ng/mL or PSAD <0.15 ng/mL/ g obtained within 30 days of registration.

_____3.1.7 Patient must have an ECOG performance status 0−1.

_____3.1.8 Patient must be willing to abstain from consumption of any supplements containing green tea catechins.

_____3.1.9 Patient must be willing to restrict tea consumption to less than three (3) servings of hot tea or three (3) servings of iced tea per week (serving size of 8 oz).

_____3.1.10 Patient must be willing to discontinue current vitamin/mineral supplement use and use one provided by study.

_____ 3.1.11 Patient must be willing to take study agent or placebo at the dose specified with meals.

_____3.1.12 Patient must have the ability to understand and the willingness to sign a written informed consent document.

_____3.1.13 Patient must not have had prior treatment for prostate cancer, including focal therapy, with surgery, irradiation, local ablative (i.e., cryosurgery or high-intensity focused ultrasound), or androgen-deprivation therapy.

Rev Add 1 _____ 3.1.14 Patient must not have a history of renal or hepatic disease, including history of hepatitis B (HBV Core Antibody) and C (HCV Core Antibody).

_____ 3.1.15 Patient must not have prostate cancer with distant metastases.

_____3.1.16 Patient must not have undergone treatment of hormone therapy, immunotherapy, chemotherapy and/or radiation for any malignancies within the past 2 years. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

_____3.1.17 Patient must not receive any other investigational agents while on this study.

_____3.1.18 Patient must not have a history of allergic reactions attributed to tea or other compounds of similar chemical or biologic composition to green tea extracts.

_____3.1.19 Patients must have adequate organ and marrow function as defined below, obtained within 30 days prior to registration:

_____Absolute neutrophil count ≥ 1,200/mm^3 (≥1.2 k/µL)

ANC:_____Date of Test: _____

_____Platelets ≥ 75,000/mm^3 (≥ 75k/µL)

Platelet:_____Date of Test: _____

_____Total bilirubin ≤ 1.2 mg/dL (or ≤ 3.0 mg/dL for patients with Gilbert's syndrome)

Bilirubin: _____

Date of Test: _____

Patient have Gilbert's syndrome? (Yes or No)

_____ AST (SGOT)/ALT (SGPT) ≤ 1.5 × ULN

AST:_____ULN: _____

Date of Test: _____

ALT:_____ULN: _____

Date of Test: _____

_____Serum creatinine ≤ 1.5 x ULN

Serum creatinine:_____ULN: _____

Date of Test: _____

_____3.1.20 Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

_____3.1.21 Sexually active males must use an accepted and effective method of double barrier contraception (vasectomy must be combined with a physical barrier method) or abstain from sexual intercourse for the duration of their participation in the study.

_____3.1.22 Patients must have archived formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen available for Gleason Score confirmation and % Ki-67 Expression (5% or more) in tumor tissue for eligibility and stratification. Tumor tissue can be submitted any time during screening.

_____3.1.22.1 Tumor tissue specimen has been collected and is ready to ship to H. Lee Moffitt Cancer Center & Research Institute as indicated in Section 10.

H. Lee Moffitt Cancer Center & Research Institute will perform Gleason Score confirmation and % Ki-67 Expression (5% or more) in tumor tissue and notify the ECOG-ACRIN Operations Office and submitting institution within 3-4 business days of receipt of the tumor tissue specimen.

3.2 Eligibility Criteria for Randomization (Step 1):

Screened patients will remain on the study and be randomized if they meet the above and following criteria. No specific timeframe between registration and randomization needs to be observed. However, as stated above intervention is to commence 6 months prior to planned prostate biopsy:

Rev Add 1

_____3.2.1 Patient must meet all Step 0 eligibility criteria at the time of their registration to Step 1.

_____3.2.2 Patient must have Gleason Score (3+3) or predominant Gleason pattern 3 (3+4), ≤ 33% of biopsy cores, and ≤ 50% involvement of any biopsy core confirmed via central review.

_____ 3.2.3 Patient must have % Ki-67 Expression of 5% or more in at least 1 core positive for tumor confirmed via central review.

_____ _____

Physician Signature Date

OPTIONAL: This signature line is provided for use by institutions wishing to use the eligibility checklist as source documentation.